International Journal of Genomics

Hindawi

Special Issue on

Advancing Genomics for Drug Development and Safety Evaluation

CALL FOR PAPERS

Genomics technologies have been widely applied to biomedical research. Taking advantage of emerging genomics technologies such as next generation sequencing (NGS), researchers could dive into detection and quantification of more aboard genomic elements (i.e., DNA, mRNA, miRNA, cirRNA, and lncRNA) to uncover the underlying diseases etiology and pathology. Furthermore, some findings and observations from the genomics space have successfully demonstrated the potential application to drug development.

We invite investigators to contribute original research articles as well as review or opinion articles that seek to address how the genomics advance drug development regarding efficacy, safety, and personalized design. A particular interest will be given to papers exploring or discussing the application of different genomic techniques such as RNAseq, DNAseq, and Mirseq to facilitate NGS-driven drug development.

Potential topics include but are not limited to the following:

- Application of RNAseq/DNAseq/Mirseq for drug safety evaluation and biomarker discovery
- Importance and significance of genomics for rare diseases and cancers
- Uncovering molecular and cellular mechanism of drug induced toxicity with genomics technology
- Integrated analysis of genomics data to address biomedical questions
- Bioinformatics methodologies and pipelines for genomics data analysis
- Analyses related to the safety assessment of drug carriers

Authors can submit their manuscripts through the Manuscript Tracking System at http://mts.hindawi.com/submit/journals/ijg/agdd/.

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor
Zhichao Liu, National Center for Toxicological Research, U.S. Food and Drug Administration, Jeffersonville, USA
zhichao.liu@fda.hhs.gov

Guest Editors
Joshua Xu, National Center for Toxicological Research, U.S. Food and Drug Administration, Jeffersonville, USA
zhihua.xu@fda.hhs.gov

Zhining Wen, Sichuan University, Chengdu, China
w_zhining@163.com

Submission Deadline
Friday, 27 October 2017

Publication Date
March 2018